Bioventus Inc. Class A (4B8)
XFRA 
Summary
4B8 Chart
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bioventus (BVS) Upgraded to Buy: Here's Why
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bioventus Inc. Class A (4B8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bioventus Inc. Class A ever had a stock split?
Bioventus Inc. Class A Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Robert Claypoole CEO | XFRA Exchange | US09075A1088 ISIN |
| US Country | 930 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.
Products and Services
Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:
- Durolane: A treatment for knee osteoarthritis providing pain relief.
- GELSYN-3: A series of injections for knee osteoarthritis pain management.
- SUPARTZ: An injectable solution for knee osteoarthritis.
- Stimrouter: A device aimed at treating chronic peripheral pain.
Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:
- Bone Graft Substitutes: Products like Osteoamp, Exponent matrix, Purebone, Signafuse bone graft, Interfuse bone graft, Osteomatrix+ synthetic bone graft, designed to stimulate bone healing.
- Ultrasonic Products: High-precision devices such as nexus ultrasonic surgical system, bonescalpel surgical solution, SonaStar, and SonicOne ultrasonic cleansing and debridement system for surgeries, including minimally invasive procedures.
- Extractor: A tool for autologous cell and bone marrow extraction to aid in bone healing.
- Reficio Bone Matrix: A novel bone graft substitute.
Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:
- Exogen: A bone healing system.
- L300 GO: A system designed to improve foot drop conditions caused by central nervous system disorders.
- H200 Rehabilitation System: A solution to aid in regaining hand function.
- Vector: A body weight support system for gait and balance training.
- Bioness Integrated Therapy System: Offers comprehensive solutions for neurorehabilitation.
The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.
